Akero Therapeutics, Inc. (AKRO)
Dec 9, 2025 - AKRO was delisted (reason: acquired by NVO)
54.65
0.00 (0.00%)
Inactive · Last trade price
on Dec 8, 2025
Akero Therapeutics Employees
Akero Therapeutics had 63 employees as of December 31, 2024. The number of employees increased by 7 or 12.50% compared to the previous year.
Employees
63
Change (1Y)
7
Growth (1Y)
12.50%
Revenue / Employee
n/a
Profits / Employee
-$4,647,937
Market Cap
4.50B
Employees Chart
AKRO News
- 5 months ago - Novo Nordisk has completed its acquisition of Akero Therapeutics - GlobeNewsWire
- 5 months ago - Akero Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Akero Therapeutics, Inc. - AKRO - Business Wire
- 5 months ago - Berger Montague PC Investigates Akero Therapeutics, Inc. and Its Board of Directors for Breach of Fiduciary Duties and Violations of Federal Securities Laws (NASDAQ: AKRO) - PRNewsWire
- 6 months ago - Akero Therapeutics Presents New Analyses from Phase 2b SYMMETRY and HARMONY Trials of Efruxifermin at 76th Annual AASLD The Liver Meeting® 2025 - GlobeNewsWire
- 7 months ago - Top Stock Movers Now: Delta Air Lines, PepsiCo, Akero Therapeutics, and More - Investopedia
- 7 months ago - Novo Nordisk to acquire Akero Therapeutics for its experimental liver disease drug - Fast Company
- 7 months ago - Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Benzinga
- 7 months ago - Akero Therapeutics soars after Novo Nordisk set for $5.2B cash acquisition - Invezz